There might be a couple cash pay people that don't mind spending $10,000 but as for medical insurance companies they will require the doctor to try the lesser expensive more effective Leronlimab before they approve spending that type of money for a patient that's not even in critical condition.
Correct. Poor countries are not going to dedicate a lot of resources to purchasing expensive monoclonal antibodies and that includes leronlimab. It is an unfortunate reality.